Merck Pitches Its Voluntary 340B Integrity Initiative to Providers as a Better Option than Audits

Merck said in letters to 340B covered entities this week that its approach to solving problems with 340B contract pharmacy transactions "is more streamlined—and less burdensome on covered entities, HRSA, and Merck—than undertaking individual manufacturer audits" of entities and their pharmacy partners.

Drug manufacturer Merck sent letters to 340B covered entities by email on Tuesday to provide background and answer questions about its request that entities voluntarily upload their contract pharmacy claims to a vendor’s software platform so they can be checked

Read More »

Feds Oppose Hospitals’ Motion to Intervene in Novo Nordisk’s 340B Lawsuit

The federal government said this week that hospital groups should not be allowed to participate as third parties in Novo Nordisk's lawsuit against the government over enforcement of its 340B contract pharmacy requirements.

The federal government on Monday strongly objected to letting six hospital groups participate as third parties in drug manufacturer Novo Nordisk’s lawsuit challenging the government’s 340B contract pharmacy requirements.

The government’s March 22 brief in opposition the groups’ motion to

Read More »

340B Dispute Resolution Injunction Is Having Ripple Effects

Sanofi is reportedly asking hospitals for data relating to 340B purchases of Dupixent.

The federal judge considering drug manufacturer Sanofi’s motion for protection from 340B dispute resolution proceedings asked the company and the federal government last Wednesday to brief her on a different federal judge’s order the day before granting drug company Eli

Read More »

Federal Judge To Get Status Report Today from Ryan White Clinics and Government

HIV/AIDS clinics' and community health centers' lawsuits to force HHS to act against drug manufacturers denying 340B pricing are both being heard in federal district court in Washington, D.C.

Ryan White Clinics for 340B Access (RWC-340B) and the federal government have a deadline today to report to a federal judge about whether to continue the stay in the group’s suit to force the government to act against drug manufacturers

Read More »

Drug Pricing Is Heating Up in Congress Again

Sen. Bernie Sanders (I-Vt.) chaired today's Senate HELP subcommittee hearing on why the United States pays the highest prices in the world for prescription drugs.

A few years ago, there was hope that congressional Democrats and Republicans and the Trump administration would unite and enact legislation addressing the high price of prescription drugs.

It never happened. House Democrats passed a far-ranging drug pricing bill in

Read More »

Health Centers Get Reprieve as 340B Insulin Pricing Rule Delayed Again

HHS has for the second time delayed the effective date of a Trump administration rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers pay for those drugs under the 340B program. The new date is July 20. | Shutterstock

The U.S. Health and Human Services Department (HHS) announced late this morning that it will delay, from this coming Monday, March 22 until July 20, the effective date of a Trump administration rule to require health centers to provide insulin

Read More »

Six Senators Reintroduce Bipartisan Bill to Protect 340B Hospitals From COVID Fallout

Sen. John Thune (R-S.D.) his and his six Senate colleagues' bipartisan bill "would ensure that no hospital that is currently participating in the 340B program can lose eligibility due to a reduction in hospitalizations during the pandemic." | C-SPAN

A bipartisan group of six U.S. senators on Tuesday reintroduced legislation from the last session of Congress to protect hospitals from losing eligibility for 340B drug discounts during the COVID-19 pandemic.

Five of the six types of hospitals that can

Read More »

Sanders Holding Senate Hearing on Drug Prices Next Week

Sen. Bernie Sanders (I-Vt.) a Senate Democratic letter to PhRMA last September decrying drug companies' denials of and conditions on 340B contract pharmacy drugs. | C-SPAN

U.S. Sen. Bernie Sanders (I-Vt.) has scheduled a hearing next Tuesday of the U.S. Senate health subcommittee he chairs on why the United States pays the highest prices in the world for prescription drugs.

The Senate Health, Education, Labor, and

Read More »

Amazon Is Opening its Employees-only Primary and Urgent Care Service to Companies Nationwide

Amazon Care, the online retailer's expanded telehealth and home-visit health care service, includes “prescription delivery right to a patient’s door.” | Amazon

Online retailer Amazon announced yesterday that it began offering companies in Washington state access to its Amazon Care telehealth and home-visit primary and urgent health care services, which include “prescription delivery right to a patient’s door.”

Until now, Amazon

Read More »

Injunction in Lilly Case Could Cause HHS to Re-Issue 340B Dispute Resolution Rule

Drug manufacturer Eli Lilly said it is pleased with a court's injunction yesterday stopping 340B dispute resolution proceedings against it over its denials of 340B pricing on contract pharmacy drugs. | Shutterstock

A federal judge’s decision to temporarily shield drug manufacturer Eli Lilly from the 340B program’s administrative dispute resolution (ADR) process could cause the government to issue 340B ADR regulations all over again, health care attorneys say.

U.S. District Judge Sarah

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live